Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 26Sarcoma 16Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Breast Neoplasms 8Recurrence 6Neoplasms 5Melanoma 4Liposarcoma 4Leiomyosarcoma 4Glioblastoma 4Fallopian Tube Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Lung Neoplasms 3Kidney Neoplasms 3Hemangiosarcoma 3Gastrointestinal Stromal Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Pancreatic Neoplasms 2Osteosarcoma 2Gliosarcoma 2

Interventions

Temozolomide 5anlotinib 43-Iodobenzylguanidine 4lutetium Lu 177 dotatate 3Specimen Handling 3cabozantinib 2belzutifan 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Everolimus 2Axitinib 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2tipifarnib 1talazoparib 1penpulimab 1pembrolizumab 1pazopanib 1olaparib 1lenvatinib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1fostamatinib 1copper dotatate CU-64 1atezolizumab 1Tamoxifen 1Sunitinib 1Ritonavir 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pheochromocytoma × pazopanib × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡